GOG-3102 MK-2870-021 Maintenance Tx in HRD-Neg OC - Clinical Trial

¿Quién puede participar en el Estudio?

Grupo etario

Adultos

Detalles del Estudio

Título Completo

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Investigador Principal